The FDA has updated statin labelling and literature to include prior screening for hepatic function. Also included in the release is the information that statins are implicated in a higher incidence( 8-13%) of diabetes in patients on them, especially with higher doses. Also highlighted is the connection, though tenous, between statin therapy and cognitive disorders.
The full article is here http://www.medscape.org/viewarticle/759588?src=cmemp.
John Vella B.Pharm. (Hons.) M.Sc.(Pharmacoeconomics)
8, Islets Promenade, Bugibba, SPB2502, Malta
+356-21571649, +356-27571649, +356-99497510